Impact Of Bronchoscopy After First-Line Chemotherapy In Patients With Stage Iv Non Small Cell Lung Cancer On Overall Survival

被引：0
|
作者：
Dayen, C. [1 ]
Trouve, C. [1 ]
Poulet, C. [2 ]
Gubler, B.
Sevestre, H. [3 ]
Suguenot, R. [1 ]
Bentayeb, H. [1 ]
Rault, I. [1 ]
Lecuyer, E. [1 ]
Hoguet, E. [4 ]
Le Meunier, F. [1 ]
Jounieaux, V. [2 ]
Benzerdjeb, N. [3 ]
Andrejak, C. [1 ]
Douadi, Y. [1 ]
机构：
[1] CHG St Quentin, St Quentin en Yvelines, France
[2] Pneumol Unit, Amiens, France
[3] Pathol Unit, Amiens, France
[4] CH Abbeville, Pneumol Unit, Abbeville, France
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3397
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Temporal Trend of Overall Survival in Patients with Advanced Non-small Cell Lung Cancer Given First-Line Cytotoxic Treatments
    Messori, Andrea
    Maratea, Dario
    Fadda, Valeria
    Trippoli, Sabrina
    LUNG, 2012, 190 (06) : 591 - 592
  • [32] Common nutritional/inflammatory indicators are not effective tools in predicting the overall survival of patients with small cell lung cancer undergoing first-line chemotherapy
    Tian, Huohuan
    Li, Guo
    Hou, Wang
    Jin, Jing
    Wang, Chengdi
    Ren, Pengwei
    Wang, Haoyu
    Wang, Jie
    Li, Weimin
    Liu, Dan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer
    Itaya, Toru
    Yamaoto, Nobuyuki
    Ando, Masahiko
    Ebisawa, Masako
    Nakamura, Yukiko
    Murakami, Haruyasu
    Asai, Gyo
    Endo, Masahiro
    Takahashi, Toshiaki
    CANCER SCIENCE, 2007, 98 (02) : 226 - 230
  • [34] Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer
    Roboubi, Amytis
    Wasielewski, Eric
    Bordier, Soraya
    Turlotte, Amelie
    Pavaut, Geoffrey
    Scherpereel, Arnaud
    Cortot, Alexis
    Gauvain, Clement
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [35] Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
    Zhang, Shuang
    Li, Shuang
    Cui, Yanan
    Zhao, Peiyan
    Sun, Xiaodan
    Cheng, Ying
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [36] First-Line Immunotherapy in Elderly Patients with Stage iv Non-Small Cell Lung Cancer: an Early Efficacy and Safety Assessment
    Kuon, Jonas
    Blasi, Miriam
    Grosch, Heidrun
    Christopoulos, Petros
    Wiedemann, Christiane
    Herth, Felix
    Heussel, Claus-Peter
    Stenzinger, Albrecht
    Thomas, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 118 - 119
  • [37] Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer
    Mencoboni, M.
    Bergaglio, M.
    Serra, M.
    Ivaldi, G. P.
    Tredici, S.
    Racchi, O.
    Rebella, L.
    Galbusera, V.
    Grosso, M.
    Faravelli, B.
    ANTICANCER RESEARCH, 2007, 27 (6C) : 4425 - 4429
  • [38] IMPACT OF PROLONGED CHEMOTHERAPY EXPOSURE ON METASTATIC NON-SMALL CELL LUNG CANCER SURVIVAL: BENEFITS OF SECOND-LINE AND EXTENDED FIRST-LINE
    De Lima Araujo, Luiz Henrique
    Baldotto, Clarissa Serodio
    Zukin, Mauro
    Vieira, Fernando Meton
    Helal, Rafaela C.
    Salem, Jonas Hauben
    Gomes, Tatiane Silva
    Almeida, Aline Negrao
    Teich, Nelson
    Ferreira, Carlos G.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1265 - S1266
  • [39] A single centre experience of first-line pembrolizumab in stage IV non-small-cell lung cancer (NSCLC)
    Denslow, R.
    Yarde, A.
    Brunner, C.
    Walther, J.
    Botten, J.
    Jankowska, P.
    LUNG CANCER, 2019, 127 : S35 - S35
  • [40] The impact of adjuvant chemotherapy on the survival of postoperative stage IIIA non small cell lung cancer patients
    Zarogoulidis, K
    Filippou, K
    Antoniou, C
    Papagiannis, A
    Hatziapostolou, P
    Tsiagga, P
    Christoforidis, M
    Kanellos, J
    2ND INTERNATIONAL CONGRESS ON LUNG CANCER, 1996, : 471 - 475
12345